Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors

Next Previous
Trial Profile

Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NEO201 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Uterine cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms QUILT-3.017
  • Sponsors Precision Biologics

    • Most Recent Events

    • 05 Apr 2024 According to a Precision Biologics media release, company will deliver a poster presentation discussing this data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, at the San Diego Convention Center in San Diego, CA on April 8th, 2024.
    • 02 Nov 2023 According to a Precision Biologics media release, company will deliver a poster presentation on preliminary results of the ongoing phase 2 trial, combining NEO-201 with pembrolizumab for the treatment of patients resistant to prior checkpoint inhibitor therapy at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting at the San Diego Convention Center in San Diego, CA on November 3rd, 2023.
    • 02 Oct 2023 According to a Precision Biologics media release, additional data regarding the effects of NEO-201 on reducing gMDSCs will be presented at the upcoming SITC Annual Meeting in San Diego in early November.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top